Rybrevant Faspro wins accelerated FDA approval in second-line head and neck cancer

What happened

On 5 November 2026 the FDA granted accelerated approval to Rybrevant Faspro, the subcutaneous co-formulation of amivantamab and hyaluronidase-lpuj, for adults with recurrent or metastatic head and neck squamous cell carcinoma whose disease progressed on or after platinum-based chemotherapy and an anti-PD-(L)1 antibody ^[1][2]. The clearance rests on OrigAMI-4 (NCT06385080), a multicenter, open-label, multi-cohort trial whose primary efficacy population was 102 patients; it excluded HPV-associated oropharyngeal disease (p16-positive) and required prior platinum chemotherapy and a PD-(L)1 inhibitor ^[1]. Patients received the drug subcutaneously every three weeks until progression ^[1]. Johnson & Johnson's release puts the overall response rate at 42% (95% CI 32-52%) ^[3]. The formulation uses Halozyme's ENHANZE delivery platform, and the approval extends amivantamab past its EGFR-mutant lung cancer roots ^[4].

Why it matters

For a developer with a program in platinum- and immunotherapy-refractory HNSCC, the number that matters is 42% (95% CI 32-52%) in 102 patients ^[3][1]. That is now a public benchmark for the second-line setting, reached by a subcutaneous regimen given every three weeks ^[1]. A competitor positioning a single-target EGFR or checkpoint asset in the same line now argues against that response rate and that route.

Who gained

The approval also flows to Halozyme, whose ENHANZE technology underpins the subcutaneous formulation ^[4]. Halozyme's 5 November 8-K reported total revenue up 39% year over year to $493 million and royalty revenue up 44% to $341 million, with raised full-year guidance, though that filing does not itself narrate the HNSCC clearance ^[5]. Separately, a Dutch specialized patent court enjoined Merck from launching Keytruda Qlex in eight European markets (Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland and the Netherlands) after finding infringement of a Halozyme ENHANZE patent ^[6]. That is platform-level context, not tied to this approval.

What to watch

This is an accelerated approval ^[1], a pathway that converts a response-rate signal into market access ahead of confirmatory evidence. Whether and when that moves toward its own filing decides how far up the treatment line this franchise reaches.

The now-what

Three moves for an operator. First, reset second-line HNSCC efficacy assumptions to the 42% public mark and test whether your asset's profile (response depth, durability, route) still separates it ^[3]. Second, if your program depends on or competes with subcutaneous co-formulation, read the Halozyme-Merck injunction as a signal that ENHANZE IP is being enforced in Europe ^[6]. Third, treat the first-line 77% dataset as the larger strategic pressure on pipeline sequencing and track it toward a regulatory filing ^[8].

What Prognyx could not verify

The dossier does not specify the confirmatory-trial commitments attached to this accelerated approval, the new label's safety and dosing detail, pricing or launch timing, or the current recruitment status of OrigAMI-4. It also contains no SEC filing that narrates the approval event itself; the 5 November Halozyme 8-K covers third-quarter earnings only ^[5].

Verdict: a moderate, near-term pressure on second-line HNSCC programs; the window to reposition is now, with the first-line expansion the larger catalyst to track.